(Q38878356)

7 September 2017

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda (English)

1 reference

7 September 2017

0 references

1 reference

7

C Kityo

1 reference

7 September 2017

3

P Mugyenyi

1 reference

7 September 2017

S R Penzak

1

1 reference

7 September 2017

G Kabuye

2

1 reference

7 September 2017

F Mbamanya

4

1 reference

7 September 2017

V Natarajan

5

1 reference

7 September 2017

R M Alfaro

6

1 reference

7 September 2017

E Formentini

8

1 reference

7 September 2017

H Masur

9

1 reference

7 September 2017

1 March 2007

1 reference

7 September 2017

1 reference

7 September 2017

8

1 reference

7 September 2017

2

1 reference

7 September 2017

86-91

1 reference

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors

7 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Single-dose nevirapine and drug resistance: the more you look, the more you find

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Functional characterization of cytochrome P450 2B6 allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00432.X

10.1111/J.1468-1293.2007.00432.X

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference